.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,026,210

« Back to Dashboard

Details for Patent: 8,026,210

Title:Exendins and exendin agonist analogs to regulate gastrointestinal motility
Abstract: Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents.
Inventor(s): Young; Andrew A. (Rancho Santa Fe, CA), Gedulin; Bronislava (Del Mar, CA)
Assignee: Amylin Pharmaceuticals, Inc. (San Diego, CA)
Filing Date:Jan 14, 2009
Application Number:12/353,861
Claims:1. A method for treating post-prandial dumping syndrome, ingestion of a toxin, or a gastrointestinal spasm in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an exendin-4 peptide comprising the amino acid sequence of SEQ ID NO:2 to treat the patient for post-prandial dumping syndrome, ingestion of a toxin, or the gastrointestinal spasm.

2. The method of claim 1, wherein the therapeutically effective amount of the exendin-4 peptide is about 0.001 mg/day to about 1 mg/day, for a 70 kg patient.

3. The method of claim 1, wherein the exendin-4 peptide is parenterally administered to the patient.

4. The method of claim 1, further comprising administering to the patient a therapeutically effective amount of an amylin or an amylin agonist analog.

5. The method of claim 1, further comprising administering to the patient a therapeutically effective amount of .sup.25,28,29Pro-human-amylin.

6. A method for treating post prandial hyperglycemia, post-prandial dumping syndrome, ingestion of a toxin, or a gastrointestinal spasm in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a peptide comprising the amino acid sequence of SEQ ID NO: 36 to treat the patient for post-prandial dumping syndrome, ingestion of a toxin, or the gastrointestinal spasm; wherein SEQ ID NO: 36 is: TABLE-US-00005 Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Gly Thr Xaa.sub.4 Xaa.sub.5 Xaa.sub.6 Xaa.sub.7 Xaa.sub.8 1 5 10 Ser Lys Gln Xaa.sub.9 Glu Glu Glu Ala Val Arg Leu 15 20 Xaa.sub.10 Xaa.sub.11 Xaa.sub.12 Xaa.sub.13 Leu Lys Asn Gly Gly Xaa.sub.14 25 30 Ser Ser Gly Ala Xaa.sub.15 Xaa.sub.16 Xaa.sub.17 Xaa.sub.18-Z 35

wherein Xaa.sub.1 is His, Arg or Tyr; Xaa.sub.2 is Ser, Gly, Ala or Thr; Xaa.sub.3 is Asp or Glu; Xaa.sub.4 is Phe, Tyr or naphthylalanine; Xaa.sub.5 is Thr or Ser; Xaa.sub.6 is Ser or Thr; Xaa.sub.7 is Asp or Glu; Xaa.sub.8 is Leu, Ile, Val, pentylglycine or Met; Xaa.sub.9 is Leu, Ile, pentylglycine, Val or Met; Xaa.sub.10 is Phe, Tyr or naphthylalanine; Xaa.sub.11 is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met; Xaa.sub.12 is Glu or Asp; Xaa.sub.13 is Trp, Phe, Tyr, or naphthylalanine; Xaa.sub.14, Xaa.sub.15, Xaa.sub.16 and Xaa.sub.17 are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine or N-alkylalanine; Xaa.sub.18 is Ser, Thr or Tyr; and Z is --OH or --NH.sub.2; with the proviso that the peptide does not comprise the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.

7. The method of claim 6, wherein: Xaa.sub.1 is His or Arg; Xaa.sub.2 is Gly; Xaa.sub.3 is Asp or Glu; Xaa.sub.4 is Phe or napthylalanine; Xaa.sub.5 is Thr or Ser; Xaa.sub.6 is Ser or Thr; Xaa.sub.7 is Asp or Glu; Xaa.sub.8 is Leu or pentylglycine; Xaa.sub.9 is Leu or pentylglycine; Xaa.sub.10 is Phe or naphthylalanine; Xaa.sub.11 is Ile, Val or t-butylglycine; Xaa.sub.12 is Glu or Asp; Xaa.sub.13 is Trp or Phe; Xaa.sub.14, Xaa.sub.15, Xaa.sub.16, and Xaa.sub.17 are independently Pro, homoproline, thioproline, or N-methylalanine; and Xaa.sub.18 is Ser or Tyr.

8. The method of claim 6, wherein the therapeutically effective amount of the peptide is about 0.001 mg/day to about 1 mg/day, for a 70 kg patient.

9. The method of claim 6, further comprising administering to the patient a therapeutically effective amount of an amylin or an amylin agonist analog.

10. The method of claim 6, further comprising administering to the patient a therapeutically effective amount of .sup.25,28,29Pro-human-amylin.

11. A method for treating post-prandial dumping syndrome, ingestion of a toxin, or a gastrointestinal spasm in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an exendin comprising the amino acid sequence of SEQ ID NO:2 or an exendin agonist analog having at least 90% sequence similarity to the amino acid sequence of SEQ ID NO: 2 to treat the patient for post-prandial dumping syndrome, ingestion of a toxin, or the gastrointestinal spasm.

12. The method of claim 11, wherein the exendin or the exendin agonist analog is a peptide comprising the amino acid sequence of any one of SEQ ID NOs: 5-35.

13. The method of claim 11, wherein the exendin or the exendin agonist analog is a peptide comprising the amino acid sequence of SEQ ID NO: 5, 6, 17, 18, 19, 22, 24, 31, 32, or 35.

14. The method of claim 11, wherein the exendin or the exendin agonist analog is a peptide comprising the amino acid sequence of SEQ ID NO: 36.

15. The method of claim 11, wherein the therapeutically effective amount of the exendin or the exendin agonist analog is about 0.001 mg/day to about 1 mg/day, for a 70 kg patient.

16. The method of claim 11, further comprising administering to the patient a therapeutically effective amount of an amylin or an amylin agonist analog.

17. The method of claim 11, further comprising administering to the patient a therapeutically effective amount of .sup.25,28,29Pro-human-amylin.

18. The method of claim 11, wherein the exendin or the exendin agonist analog is parenterally administered to the patient.

19. The method of claim 1 for treating post-prandial dumping syndrome.

20. The method of claim 6 for treating post-prandial dumping syndrome.

21. The method of claim 11 for treating post-prandial dumping syndrome.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc